Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06708624 · ClinicalTrials.gov registry record · Phase 4

Ocular Safety and Usability Study for FYB201 PFS

A Phase 4 study of Age-related Macular Degeneration and Central Retinal Vein Occlusion With Macular Edema, sponsored by Formycon.

Completed
Registry status
Phase 4
Development phase
31
Enrollment target
4
Study locations

NCT06708624 is a Phase 4 study of Age-related Macular Degeneration and Central Retinal Vein Occlusion With Macular Edema that has completed, run by Formycon. The registered enrollment target is 31 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06708624, a Phase 4 study of Age-related Macular Degeneration and Central Retinal Vein Occlusion With Macular Edema, has completed, sponsored by Formycon.

COMPLETED
Registry status
Phase 4
Development phase
31 participants
Enrollment target
4
Study locations

Study Summary

The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.

Interventions

  • DRUG FYB201 0.5 mg (0.05 mL of 10 mg/mL)

Study Locations (4)

California

  • Research Site - Campbell
  • Research Site - Long Beach

Maryland

  • Research Site - Hagerstown

Oregon

  • Research Site - Eugene

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2024-06-11
Est. Completion 2024-08-08
Phase Phase 4

Sponsor

Formycon

2 total trials

What the Registry Record Tells You About NCT06708624

The ClinicalTrials.gov registry entry for NCT06708624 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The listed sponsor is Formycon, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which FYB201 0.5 mg (0.05 mL of 10 mg/mL) is the first listed.

NCT06708624 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, Oregon.

Frequently Asked Questions

What is clinical trial NCT06708624 about?

NCT06708624 is a clinical study titled "Ocular Safety and Usability Study for FYB201 PFS". The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.

What is the current status of trial NCT06708624?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2024-06-11. Estimated completion is 2024-08-08.

What conditions does trial NCT06708624 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion with Macular Edema.

What interventions are being tested in trial NCT06708624?

The interventions under investigation include: FYB201 0.5 mg (0.05 mL of 10 mg/mL) (DRUG).

Who is sponsoring clinical trial NCT06708624?

This trial is sponsored by Formycon, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06708624 being conducted?

This trial has 4 study locations across California, Maryland, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.